SCHEMBL2483276

SCHEMBL2483276

CC(=O)Nc1cc(-c2c(-c3cccc(O)c3)nn3ccsc23)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.43
MAPK14 Q16539 4/20 0.42
ABL1 P00519 2/20 0.42
GSK3B P49841 1/20 0.42
CSNK1D P48730 1/20 0.39
EGFR P00533 1/20 0.39
FYN P06241 3/20 0.38
PIK3C3 Q8NEB9 7/20 0.38
BUB1 O43683 2/20 0.36
ERN1 O75460 1/20 0.36
RAF1 P04049 1/20 0.36
FGFR1 P11362 1/20 0.36
BRAF P15056 1/20 0.36
FLT3 P36888 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK11 Q15759 1/20 0.36
NTRK2 Q16620 1/20 0.36
HIPK1 Q86Z02 1/20 0.36
MAP3K20 Q9NYL2 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477533 0.79 FYN (0.42) ADORA2AMAPK14GSK3BEGFRFYN
SCHEMBL2477784 0.74 BRAF (0.41) MAPK14ABL1EGFRFYNRAF1
SCHEMBL2478694 0.74 KDM4E (0.40) ADORA2AMAPK14ABL1CSNK1DEGFR
SCHEMBL14844912 0.72 KDM4E (0.45) MAPK14ABL1GSK3BCSNK1DEGFR
SCHEMBL2477342 0.71 PIK3C3 (0.49) PIK3C3BRAF
SCHEMBL16008517 0.67 PTGS2 (0.57) MAPK14GSK3BCSNK1DMAPK11
SCHEMBL19706503 0.66 PIK3C3 (0.51) PIK3C3
SCHEMBL2478578 0.66 MAPK14 (0.47) MAPK14RAF1BRAFMAPK11TP53
SCHEMBL2477772 0.65 BRAF (0.47) MAPK14EGFRFGFR1BRAFTP53
SCHEMBL19736191 0.65 L3MBTL1 (0.57) PIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US claimed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP claimed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US claimed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP claimed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO claimed
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 ADORA2A 3678/4885MAPK14 60/4885ABL1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.